Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 second quarter operational and financial results after market close on Tuesday, February 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 second quarter operational and financial results after market close on Tuesday, February 3, 2026. The company will host a conference call and live webcast the same day at 4:30 p.m. Eastern time followed by a Q&A session.
Call-in numbers: (888) 506-0062 (U.S.) and +1 (973) 528-0011 (international) using participant access code 567381. The webcast will be available live and archived at the provided webcast link and on the Investors section of the company website under Events & Presentations. A teleconference replay will be available through February 17, 2026 at (877) 481-4010 (U.S.) or +1 (919) 882-2331 (international) using replay access code 53322.
Details
News Market Reaction – AYTU
On Jan 28, the first trading day after this news, AYTU closed 0.77% above the previous close.
Data tracked by StockTitan Argus for the Jan 28 session.
Key Figures
- Earnings release date
- February 3, 2026
- Fiscal 2026 Q2 operational and financial results release
- Earnings call time
- 4:30 p.m. Eastern time
- Fiscal 2026 Q2 conference call and webcast
- US dial-in
- (888) 506-0062
- Conference call access for U.S. participants
- International dial-in
- +1 (973) 528-0011
- Conference call access for international participants
- Participant access code
- 567381
- Code required to join fiscal 2026 Q2 call
- Replay end date
- February 17, 2026
- End of teleconference replay availability window
- Replay US dial-in
- (877) 481-4010
- Teleconference replay access for U.S. callers
- Replay international dial-in
- +1 (919) 882-2331
- Teleconference replay access for international callers
Historical Context
-
Recap of Investor Day focused on EXXUA Phase 3 data and opportunity.
-
Nationwide launch of EXXUA for major depressive disorder in adults.
-
CEO fireside chat at Lytham Partners 2026 Investor Healthcare Summit.
-
Details on planned EXXUA‑focused Investor Day presentations and webcast.
-
Announcement of January 20, 2026 Investor Day centered on EXXUA.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 567381.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53322, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until February 17, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53322.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.